NCT04136067View on ClinicalTrials.gov

A Study to Look at How Safe NNC0268-0965 is in People With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 29, 2019

Primary Completion Date

August 23, 2020

Study Completion Date

August 23, 2020

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

NNC0268-0965

One daily dose of 1.5, 4.0 or 6.0 nmol/kg administered s.c. (subcutaneously, under the skin) for 6 days

DRUG

insulin glargine

One daily dose of 3.0 nmol/kg administered s.c. for 6 days

Trial Locations (1)

41460

Novo Nordisk Investigational Site, Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY